The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Patients who have been started on Pradaxa in accordance with the approved label in Korea

Patients who have signed on the data release consent form

Exclusion criteria:

Patients with previous exposure to Pradaxa

Clinically significant bleeding

Increased risk of bleeding due to following diseases;

Recent gastrointestinal ulceration

Recent intracranial or intracerebral bleeding history

Intraspinal or intracerebral vascular abnormalities

Recent brain, spinal or ophthalmic surgery

Recent brain or spinal injury

Known or suspected oesophageal varices

Arteriovenous malformations

Vascular aneurysms

Presence of malignant neoplasms at high risk of bleeding

Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc), oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under the circumstances of switching therapy to or from Pradaxa or when UFH is given at doses necessary to maintain an open central venous or arterial catheter

Severe renal impairment (CrCl < 30mL/min)

Concomitant treatment with oral ketoconazole or dronedarone

Patients hypersensitive to dabigatran or dabigatran etexilate or to any ingredient in the formulation

Prosthetic heart valve replacement

No creatinine clearance collected within at least one year prior to enrollment

Current participation in other clinical trials

Sex/Gender

Sexes Eligible for Study:

All

Ages

18 Years and older (Adult, Senior)

Accepts Healthy Volunteers

No

Contacts

Contact information is only displayed when the study is recruiting subjects